piperidines and Parkinson-Disease--Postencephalitic

piperidines has been researched along with Parkinson-Disease--Postencephalitic* in 2 studies

Trials

1 trial(s) available for piperidines and Parkinson-Disease--Postencephalitic

Article	Year
Dissociation of antitremorine activity and clinical antiparkinsonian effect. A clinical trial of AGN 511 in postencephalitic parkinsonism. Arzneimittel-Forschung, 1970, Volume: 20, Issue:12 Topics: Animals; Barbiturates; Humans; Mice; Parasympatholytics; Parkinson Disease, Postencephalitic; Piperidines; Tremor; Tremorine	1970

Other Studies

1 other study(ies) available for piperidines and Parkinson-Disease--Postencephalitic

Article	Year
Lisuride in parkinsonism. Annals of neurology, 1981, Volume: 9, Issue:1 Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations. Topics: Administration, Oral; Aged; Benzimidazoles; Chorea; Domperidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Growth Hormone; Humans; Injections, Intravenous; Lisuride; Male; Middle Aged; Paralysis; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Piperidines; Prolactin	1981

Article

Year

Lisuride in parkinsonism.

Annals of neurology, 1981, Volume: 9, Issue:1

Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.

Topics: Administration, Oral; Aged; Benzimidazoles; Chorea; Domperidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Growth Hormone; Humans; Injections, Intravenous; Lisuride; Male; Middle Aged; Paralysis; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Piperidines; Prolactin

1981